Skip to main content

Dexcom Value Stock - Dividend - Research Selection

Dexcom

ISIN: US2521311074 , WKN: A0D9T1

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop a series of next-generation CGM products; and a collaboration with Companion Medical, Inc. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Why DexCom, Inc. (DXCM) Went Up On Friday

2025-05-03
We recently published a list of What Propelled These 10 Firms’ Double-Digit Gains? In this article, we are going to take a look at where DexCom, Inc. (NASDAQ:DXCM) stands against other Friday’s top performers. The stock market ended the trading week on a strong note, with all major indices clocking in strong gains, as investors cheered […]

S&P 500 Gains and Losses Today: Index Climbs as Strong Jobs Report Alleviates Economic Concerns

2025-05-02
The S&P 500 jumped 1.5% on Friday, May 2, 2025, as the latest jobs report revealed a strong pace of hiring in April despite tariff-related uncertainties.

DexCom Stock Rockets Higher To Lead S&P 500 Gainers

2025-05-02
Shares of DexCom jumped over 15% to pace the S&P 500's advancers Friday, a day after the maker of glucose monitoring devices for people with diabetes reported better-than-expected quarterly revenue.

Top Midday Gainers

2025-05-02
Smart Digital Group (SDM) said late Thursday that it priced its initial public offering of 1.5 milli

DexCom (NasdaqGS:DXCM) Announces US$750M Buyback and Reiterates 2025 Earnings Guidance

2025-05-02
DexCom (NasdaqGS:DXCM) recently announced a $750 million share buyback program and reaffirmed its revenue growth guidance of 14% for 2025, coinciding with its earnings report for the first quarter showing increased sales but decreased net income. In the past month, the company's share price saw a 4% rise, bolstered by broader market gains, as the S&P 500 extended a notable winning streak and investor sentiment was uplifted by strong employment data. Despite fluctuations due to Dexcom's mixed...

DexCom Stock Rises Despite Q1 Earnings Miss & Lower Margins

2025-05-02
DXCM's first-quarter 2025 earnings decline despite increasing sales. Its performance in 2025 is expected to be fueled by global growth in CGM adoption, strong Sensor sales and expansion into new markets.

Top Stock Movers Now: Dexcom, Berkshire Hathaway, Nvidia, and More

2025-05-02
The economy created more jobs than anticipated in April, sending U.S. equities higher at midday.

Dexcom Stock Is Today’s Big Winner After Earnings. Why the Medtech Is Soaring.

2025-05-02
Dexcom the maker of continuous glucose monitoring systems, posted stronger-than-expected earnings in the first quarter. The figure represented 12% growth on a reported basis and 14% on an organic basis. Shares of the medical technology company climbed 16% to $81.42 on Friday and were headed for their largest same-day percentage increase since Oct. 28, 2022, according to Dow Jones Market Data.

Q1 2025 Dexcom Inc Earnings Call

2025-05-02
Q1 2025 Dexcom Inc Earnings Call

2 Growth Stocks to Buy and Hold for a Decade

2025-05-02
MercadoLibre's business should not feel a direct impact from tariffs. DexCom has a significant growth runway in a market where it's a leader. Marketwide challenges, like those created by President Donald Trump's tariff policies, cause many investors to shift their focus to the short term -- leading to panic-selling and a spiraling stock market.